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Abstract
Despite intense interest and considerable effort via high-throughput screening, there are few examples of small molecules
that directly inhibit protein-protein interactions. This suggests that many protein interaction surfaces may not be
intrinsically ‘‘druggable’’ by small molecules, and elevates in importance the few successful examples as model systems for
improving our fundamental understanding of druggability. Here we describe an approach for exploring protein fluctuations
enriched in conformations containing surface pockets suitable for small molecule binding. Starting from a set of seven
unbound protein structures, we find that the presence of low-energy pocket-containing conformations is indeed a
signature of druggable protein interaction sites and that analogous surface pockets are not formed elsewhere on the
protein. We further find that ensembles of conformations generated with this biased approach structurally resemble known
inhibitor-bound structures more closely than equivalent ensembles of unbiased conformations. Collectively these results
suggest that ‘‘druggability’’ is a property encoded on a protein surface through its propensity to form pockets, and inspire a
model in which the crude features of the predisposed pocket(s) restrict the range of complementary ligands; additional
smaller conformational changes then respond to details of a particular ligand. We anticipate that the insights described here
will prove useful in selecting protein targets for therapeutic intervention.
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Introduction
Manipulating the interactions between proteins represents a
promising avenue for therapeutic intervention in a variety of
settings. Given the ubiquitous nature of protein interactions,
selectively manipulating such interactions could serve as a means
to treat conditions including viral and bacterial infections, cancer,
and autoimmune disorders [1–7]. In spite of recent ongoing efforts
that have provided cause for optimism, protein interactions
continue to be viewed as a challenging class of therapeutic target
[8–12]. While high-throughput screening efforts that fail to yield
extensive hits are typically not reported in the literature, hit rates
as low as 0.01% in a large pharmaceutical library have been
described [13].
This dearth of successful representatives to study has given
increased importance to the several cases in which a protein
structure has been solved in complex with a biological protein
partner and also in complex with a small molecule inhibitor. Wells
and McClendon [8] compared six such cases and observed that
binding was not associated with a large conformational change in
any of these examples; and yet, the concave pocket on the protein
surface at which the small molecule binds was typically smaller or
not present in the unbound protein structure. In order for inhibitor
binding to occur, the surface of the unbound structure therefore
had to undergo local rearrangement to reveal a small molecule
binding site that would not necessarily be evident from the
unbound structure [8].
Given the limited success in identifying modulators of protein-
protein interactions, it has proven helpful at an early stage to
validate a protein surface site by evaluating its ‘‘druggability’’. As
such, fragment-based methods have been developed to experi-
mentally assess the druggability of a protein interaction site by
determining which members of a small molecule probe set bind to
a target protein, and where on the protein surface these bind. This
experiment can be conducted using ‘‘SAR by NMR’’ [14], which
tracks chemical shift differences to identify binding sites on the
protein surface, or by the ‘‘multiple solvent crystal structures’’
method [15], in which independent structures of the target protein
are solved after soaking with a collection of organic solvents. Both
of these approaches aim to probe the regions of a protein surface
that can accommodate small-molecule binding, with a preference
for sites that are not uniquely disposed to bind a particular pre-
selected ligand. In either technique, specific regions of the protein
surface that interact with a variety of probe molecules – albeit
weakly – are inferred to be a putative site for more potent binding
by some yet unidentified compound.
Inspired by these methods, we hypothesize that the ability to
form a binding pocket may be the limiting factor for druggability
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of a protein surface site. We further propose that compounds
identified in biochemical screens as inhibitors of protein interac-
tions result from natural shape complementarity to specific surface
pockets that form with little energetic cost to the protein. Together
these hypotheses imply that druggable sites differ from the rest of
the protein surface, in that fluctuations under physiological
conditions at druggable sites include a special subset of ‘‘pocket-
containing’’ conformations.
To test these hypotheses, we have developed computational
methodology to explore protein fluctuations in a biased way, by
providing a driving force towards conformations in which a
surface pocket is present. Several other studies have generated
ensembles of protein conformations reflecting fluctuations around
the native state and used these either to assess druggability [16] or
as a starting point for docking studies [17–24]. Because these
ensembles are generated in an unbiased manner, however, a large
fraction of the resulting ensembles correspond to protein
conformations that are dissimilar to the corresponding bound
structure in both pocket size and hydrophobicity [18]. One of
these studies found that carrying out simulations in methanol led
to formation of surface pockets which could accommodate small
molecules [25], but the use of this non-biological solvent may lead
to unphysical artifacts in the resulting models. Molecular dynamics
has also been used in a computational analog of ‘‘SAR by NMR’’
in which simulations are carried out using an explicit mixed
solvent, allowing druggable sites to be identified by locating
accumulation of probe molecules [17,20,26]. Though these
methods proved effective for binding sites, the unbiased nature
of the underlying simulations make these approaches very
computationally intensive. Recently Kozakov et al. have devel-
oped a computational analog of the multiple solvent crystal
structures method, by using docking to identify ‘‘consensus’’ sites
at which several probe molecules cluster [27]. They confirmed that
these molecular probes indeed cluster at established druggable sites
and that known inhibitors often occupy these consensus sites. Such
an approach, however, cannot efficiently explore surface pockets
that form via concerted motions involving the protein backbone
due to the computational expense associated with repeatedly
docking multiple small molecule probes. The biasing potential we
describe here avoids this limitation by not needing to dock probe
molecules, and therefore can be used in the course of a simulation
that samples a broader range of conformational fluctuations.
Results
Quantitative analysis of surface pockets
Because a wide, shallow pocket that is unsuitable for small
molecule binding can have the same volume as a deep pocket that
is more suitable for small molecule binding, we introduce the
concept of ‘‘deep’’ volume of a pocket: the volume of the pocket
that is well-sequestered away from solvent. To quantitatively
identify small molecule binding pockets and measure their ‘‘deep’’
volume, we implemented a modified version of the LIGSITEcs
algorithm [28]. This approach starts by creating a grid around a
protein and marking each grid point as occupied by protein,
surface, or solvent. Next, the algorithm performs linear searches
on the grid to find ‘‘Surface-Solvent-Surface’’ events: lines drawn
between two surface points that pass through only solvent (Figure
S1), indicating a concave region on the protein surface. To
distinguish between total pocket volume and deep volume, pocket
points that fall within 2.5 Å of solvent are marked as ‘‘surface
pocket’’ points and are excluded from the ‘‘deep volume’’
calculation. Finally, the remaining contiguous points involved in
these events are clustered into ‘‘deep pockets’’. As expected, the
deep pocket volumes we use here are correlated to, but smaller
than, pocket volumes found by other pocket detection methods,
such as Q-SiteFinder [19] (Figure S2). Our implementation
differs from the original LIGSITEcs algorithm [28] in that our
search is restricted to the region around a specific ‘‘target’’ residue
on the protein surface, allowing us to rapidly test for pockets at a
specific surface site. Additional minor differences are described in
Text S1.
A demonstration of this method is shown in Figure 1A. Bcl-XL
is an anti-apoptotic protein in the Bcl-2 family whose over-
expression has been implicated in the survival of cancer cells. A
series of acyl-sulfonamide-based ligands have been shown to
inhibit Bcl-XL activity by competing for its peptide-binding
groove. Here, we have removed one such inhibitor from a co-
crystal structure and applied our modified implementation of the
LIGSITEcs algorithm at this surface site. The resulting pocket has
intuitive shape complementarity to the ligand even though it was
generated from the protein structure without the ligand present.
This is unsurprising, given that the ligand occupying this pocket is
complementary in shape to the protein surface.
We compiled a test set of all seven proteins for which structures
have been solved both alone and in complex with a small-molecule
inhibitor bound to a protein interaction site (Bcl-XL, IL-2,
FKBP12, HPV E2, ZipA, MDM2, and the BIR3 domain of
Figure 1. Identifying surface binding pockets. (A) Bcl-XL (grey
surface) is shown in complex with an inhibitor (blue sticks). The protein
surface features a large pocket (red spheres) complementary in shape to
the inhibitor. (B) Deep pocket volumes of surface pockets at protein
interaction sites harboring a bound inhibitor (red line) are larger than
those found elsewhere on the protein surface (black line). Data are
collected from a test set of seven proteins, each of which has been
solved in complex with a small-molecule inhibitor (Bcl-XL, IL-2, FKBP12,
HPV E2, ZipA, MDM2, and the BIR3 domain of XIAP).
doi:10.1371/journal.pcbi.1002951.g001
Author Summary
Identifying small-molecule inhibitors of protein interac-
tions has traditionally presented a challenge for modern
screening methods, despite interest stemming from the
fact that such interactions comprise the underlying
mechanisms for cell proliferation, differentiation, and
survival. This suggests that many protein interaction
surfaces may not be intrinsically ‘‘druggable’’ by small
molecules, and elevates in importance the few successful
examples as model systems for improving our under-
standing of factors contributing to druggability. Here we
describe a new approach for exploring protein fluctuations
leading to surface pockets suitable for small molecule
binding. We find that the presence of such pockets is
indeed a signature of druggable protein interaction sites,
suggesting that ‘‘druggability’’ is a property encoded on a
protein surface through its propensity to form pockets. We
anticipate that the insights described here will prove
useful in selecting protein targets for therapeutic inter-
vention.
Druggability of Protein Interaction Sites
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XIAP) (Table 1). We compared the deep pocket volume at
randomly selected regions of the protein surface (see Text S1) to
the deep volume of the inhibitor-bound pocket. Since the pocket
definition can depend somewhat on the particular ‘‘target’’ residue
used, the deep volume of the inhibitor-bound pocket was
measured several times using different target residues. As shown
in Figure 1B, across all seven proteins, most pockets identified by
this algorithm at randomly selected sites (black line) on the protein
surface have a deep volume smaller than 25 Å3, and all are smaller
than 75 Å3. In contrast, the distribution of inhibitor-bound pocket
volumes (red line) is significantly shifted, with about half of the
inhibitor-bound deep pocket volumes larger than 75 Å3. This
observation is consistent with results generated using other pocket
detection methods [29–33], although those other studies were not
focused on inhibitors of protein-protein interactions.
Druggability of protein surface sites
The results presented above demonstrate that inhibitor binding
occurs at surface sites containing a pocket, and that these sites are
distinct from the remainder of the protein surface. We therefore
formulated the hypothesis that the ability of the protein surface to
form such pockets may be the limiting determinant of the inherent
druggability at this site.
Unlike previous standalone methods for pocket detection, we
instead implemented our algorithm as a term in the Rosetta [34]
energy function alongside the canonical energetic determinants of
protein structure such as packing, hydrogen bonding, and
solvation (see Methods section). By including this biasing term in
the energy function, we may use any of the standard functionalities
provided in Rosetta; inclusion of this term, meanwhile, will lead to
simultaneous optimization of both ‘‘pocket score’’ and the
traditional energy terms. In essence, the contribution from the
‘‘pocket’’ term serves as a proxy for the energy associated with
binding of some (unspecified) small molecule partner.
To test the hypothesis that pocket formation may be the limiting
determinant of druggability, we performed biased and unbiased
simulations on the unbound conformations of Bcl-XL, targeting
residues at the protein interaction site as well as at equivalent
randomly selected residues elsewhere on the protein surface.
Surface sites included in the random set were matched to those at
the protein interaction site on the basis of their secondary
structure, and further that a contacting pocket of equivalent size to
that of the protein interaction site (evaluated by Q-SiteFinder [19])
was present in the unbound conformation (see Text S1 and
Figure S3); further, the random sites were each at least 12 Å from
one another. Both backbone and sidechain degrees of freedom
were allowed to move during simulations (see Methods section).
The deep pocket volumes from each of 1,000 conformations
generated via each method are shown as cumulative histograms in
Figure 2A. Pockets at the protein interaction site (solid red lines)
form more often and are significantly larger than those formed
elsewhere on the protein surface (dashed black lines). The largest
pockets in the biased simulations are sampled with much higher
frequency than in the corresponding unbiased simulations
(Figure 2A), demonstrating that the biasing potential drives
sampling towards these conformations. These observations further
hold for each of the other six additional proteins comprising our
test set (Figures 2B–G), and also after inclusion of additional
random sites (Figure S4) or starting from the protein-bound
conformation (Figure S5).
To examine the physiological relevance of the conformations
generated in biased simulations, we compared their energies to
those obtained in equivalent unbiased simulations. For Bcl-XL, we
used Rosetta to evaluate the (unbiased) energy for each of 1000
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(Å
3
)
A
ff
in
it
y
o
f
m
o
st
p
o
te
n
t
k
n
o
w
n
in
h
ib
it
o
r
(n
M
)
M
D
M
2
p
5
3
4
9
2
1
1
9
1
2
9
1
5
0
2
0
1
1
9
4
8
0
Z
ip
A
Ft
sZ
3
2
8
1
3
9
9
1
1
6
6
6
1
9
2
1
2
,0
0
0
B
cl
-x
L
B
ak
2
3
3
1
4
1
2
0
0
3
7
7
3
4
2
2
1
0
0
.5
X
IA
P
SM
A
C
4
9
7
1
1
7
1
5
8
2
7
4
0
3
2
3
6
7
IL
-2
IL
-2
R
1
5
3
1
2
8
3
8
3
8
3
8
1
7
7
6
0
H
P
V
E2
H
P
V
E1
3
6
7
1
9
3
9
3
9
2
1
3
2
1
2
9
4
0
FK
B
P
1
2
T
b
e
ta
1
-R
1
0
8
1
0
7
9
0
1
2
4
1
4
5
1
1
6
7
d
o
i:1
0
.1
3
7
1
/j
o
u
rn
al
.p
cb
i.1
0
0
2
9
5
1
.t
0
0
1
Druggability of Protein Interaction Sites
PLOS Computational Biology | www.ploscompbiol.org 3 March 2013 | Volume 9 | Issue 3 | e1002951
conformations generated from an unbiased simulation, a simula-
tion with the biasing term applied to either the protein interaction
site or a random surface residue, and equivalent simulations in
which the weight of the biasing term was increased tenfold. In all
cases we evaluated energies without contribution from the biasing
term; a histogram of these energies is shown in Figure 3A.
Conformations from the unbiased simulation (green solid line) have a
very similar distribution of energies as conformations from a
simulation in which the biasing potential was applied to a
randomly selected target residue (black dashed line); this is
unsurprising given that few of these conformations contain
pockets, implying that a similar ensemble of conformations are
sampled. Applying a stronger weight to the biasing potential using
the same randomly selected target residue (solid black line) leads to
conformations that are far less energetically favorable, indicating
that pocket opening to satisfy the biasing potential could not be
achieved without extensive energetic cost to the protein. In
contrast, applying the biasing potential to a residue at the protein
interaction site led to conformations that were only slightly higher
in energy (and with overlapping distributions) than those
conformations sampled in the unbiased simulation, for either
weight of the biasing potential (red lines). A scatterplot showing the
deep pocket volume for each of these conformations highlights the
fact that conformations containing large pockets are sampled with
the moderate biasing potential only if it is applied at the protein
interaction site (Figure 3B, cyan vs. red points). Application of the
stronger biasing potential to random (carefully matched) surface
sites leads to generations of low-energy conformations without
large pockets, and also pocket-containing conformations with
much higher energy (Figure 3B, blue points).
The same observations also hold for each of the other six
proteins comprising our test set (Figure S6, Table 1). Collec-
tively, these results demonstrate that pocket opening at the
druggable site can occur with little energetic cost to the protein,
while pocket opening elsewhere on the protein surface requires
that the protein adopt a highly unfavorable conformation.
It is notable that in each of these seven examples surface pockets
were identified at the protein interaction site. It is equally notable,
however, that similar surface pockets were not observed elsewhere
on the protein surface (Figure 2). This comparison highlights the
qualitative difference between the protein interaction site – already
demonstrated to be druggable in a practical sense for each of these
examples – and the remainder of the protein surface, at which
high-affinity interactions with small molecules have not been
observed.
Pocket shapes are encoded on the protein surface
The results presented above demonstrate that there is a natural
predisposition towards pocket formation in certain druggable
regions on the protein surface. We next asked whether these
preferred pocket-containing conformations dictate the range of
potential small-molecule inhibitors suitable for binding at this site.
Should this be the case, protein conformations generated using a
biasing potential to induce pocket formation should resemble
inhibitor-bound conformations more than conformations gener-
ated using an equivalent unbiased protocol.
Turning first to Bcl-XL, we aligned the lowest-energy confor-
mation produced from the biased simulations described earlier
Figure 2. Surface pockets emerge only at druggable sites.
Volumes of surface pockets are shown from conformations generated
with no biasing potential (left) and upon inclusion of a ‘‘pocket
opening’’ biasing potential (right) for each of the seven proteins that
comprise our test set. Surface pockets occur at druggable protein
interaction sites (solid red lines) more frequently than elsewhere on the
protein surface (dashed black lines). (A) Bcl-XL. (B) IL-2. (C) FKBP12. (D)
HPV E2. (E) ZipA. (F) MDM2. (G) BIR3 domain of XIAP.
doi:10.1371/journal.pcbi.1002951.g002
Druggability of Protein Interaction Sites
PLOS Computational Biology | www.ploscompbiol.org 4 March 2013 | Volume 9 | Issue 3 | e1002951
(which were started from the unbound protein structure) to both
unbound and inhibitor-bound crystal structures (Figure 4A).
Direct superposition of the inhibitor from the bound structure
onto the unbound crystal structure reveals extensive steric clashes
(Figure 4B), highlighting the local protein conformational
changes that must take place in order for inhibitor binding to
occur. Remarkably, examination of the conformation from the
biased simulation shows that part of the protein surface has
adopted a shape highly complementary to the inhibitor
(Figure 4C, right side) – even though no information about
the identity of the inhibitor was included in the simulation that
produced this conformation. Further, this conformational change
occurred without direct involvement of the ‘‘target’’ residue at
which the biasing term was applied.
On the other hand, the conformation from the biased
simulation did not recapitulate the bound conformation exactly:
the latter contains an extension to the surface pocket (left side in
the orientation shown) to accommodate the ‘‘tail’’ of the
inhibitor (Figure 4D). Comparison of the protein backbone in
all three structures (Figure 4A) reveals the protein structural
reorganization required to accommodate this ‘‘tail’’: the helix
below the inhibitor (Figure 4A, foreground) unwinds on the
left side, and tightens on the right side (in the orientation shown).
Because the deep pocket volume is larger in the inhibitor-bound
crystal structure than in the conformation from the biased
simulation, we anticipate that sampling in these simulations was
insufficient to fully recapitulate this highly concerted conforma-
tional change.
The diversity of conformational changes associated with
inhibitor binding in different proteins is highlighted in Figure
S7. In IL-2, slight rearrangement of a helix (at top of the
orientation shown) allows a sidechain rotamer change that both
reveals the binding pocket and creates new interactions with
inhibitor shown (Figure S7A). In contrast FKBP12, HPV E2 and
ZipA each contain a pre-formed pocket on the unbound protein
surface that strongly complements the inhibitor, indicating that
inhibitor binding occurs primarily via a ‘‘lock-and-key’’ mecha-
nism in these cases (Figure S7B–D). Expansion of the ZipA
pocket observed in the biased simulations (Figure 2E) resulted
from sidechain rearrangement on the surface to the left side of the
binding site (in the orientation shown), without disrupting the pre-
ordered portions of the binding site. Nutlin binding to MDM2, on
the other hand, requires splaying apart of two surface helices to
create the binding pocket: this conformational change is dramat-
ically recapitulated in the lowest-energy individual conformation
from the biased simulations (Figure S7E). Finally, unlike these
previous examples showing modest conformational changes,
binding of a Smac-mimetic to the BIR3 domain of XIAP is
Figure 3. Energetic analysis of Bcl-XL pocket opening. (A)
Conformations generated without the use of a biasing potential (solid
green line) show a similar distribution of energies to those generated
with the biasing potential at a randomly selected target residue (dashed
black line); increasing the strength of the biasing potential here leads to
conformations with higher energies (solid black line). In contrast,
application of the biasing potential at the protein interaction site (red
lines) leads to conformations with a distribution of energies that
strongly overlaps with those energies of conformations sampled in the
unbiased simulations, suggesting that these conformations represent
low-energy states accessible to the unbound protein. (B) A scatterplot
showing the deep pocket volume for conformations generated with the
biasing potential applied to one of the random sites (moderate bias in
cyan, strong bias in blue) or to the protein interaction site (moderate bias
in red, strong bias in orange). Low-energy conformations containing
large pockets are sampled only if the biasing potential it is applied at
the protein interaction site; while large pockets are sampled using the
strong bias at random sites, these conformations have considerably
higher energy. All energies shown here were evaluated in the absence
of the biasing potential, for fair comparison.
doi:10.1371/journal.pcbi.1002951.g003
Figure 4. Representative conformations of Bcl-XL. An unbound
crystal structure (pink), an inhibitor-bound crystal structure (green, with
inhibitor shown in sticks), and a low-energy conformation generated
from the unbound crystal structure using the biasing potential (cyan,
with target residue in red) are shown. (A) The overall protein architecture
is preserved amongst all three; movement of the helix in the
foreground upon binding is not recapitulated in the pocket-opened
conformation. (B–D) The pocket revealed in this low-energy confor-
mation nonetheless strongly resembles the surface pocket in the bound
crystal structure, and even bears shape-complementarity to the
inhibitor. The identity of the inhibitor was not used in generating this
conformation, but was added retrospectively for visual comparison.
doi:10.1371/journal.pcbi.1002951.g004
Druggability of Protein Interaction Sites
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associated with extensive rearrangement of long surface loops
(Figure S7F).
To assess whether the protein conformations generated using
the biasing potential resemble inhibitor-bound conformations
more closely than conformations generated using an equivalent
unbiased protocol, we quantitatively compared the ensembles of
conformations produced by each method. We note that neither
method uses any knowledge of any particular inhibitor when
generating an ensemble of conformations. Therefore, rather than
report the protein RMSD in reference to one pre-selected bound
conformation we instead individually computed the interface
RMSD (iRMSD) relative to every available inhibitor-bound
crystal structure (see Text S1), and took the lowest of this set of
iRMSD values to reflect the suitability of this conformation for
binding some (known) unspecified inhibitor.
For each of the seven proteins in our test set described earlier,
we show the iRMSD for each member of the biased and unbiased
ensembles to its closest inhibitor-bound crystal structure
(Figure 5). We note that the iRMSD values of conformations
sampled vary across these seven different proteins; this stems from
the fact discussed earlier that in some cases the unbound starting
structure strongly resembles the inhibitor-bound structure
(FKBP12, HPV E2, ZipA), while in other cases a more extensive
conformational change accompanies binding (MDM2, XIAP)
(Figure S7). For reference, we also indicate the iRMSD of the
unbound starting structure relative to the closest and most distant
inhibitor-bound structures (Figure 5, dashed brown lines) and the
protein-bound structure relative to the closest and most distal
inhibitor-bound structures (Figure 5, dashed green lines).
Though there is overlap between the resulting distributions, for
every one of the seven proteins we examined the conformations
sampled in the biased simulations are closer to an inhibitor-bound
conformation than the conformations sampled in the correspond-
ing unbiased simulations. This observation applies not just to the
iRMSD of atoms directly involved in binding (Figure 5), but to
the backbone atoms of the corresponding residues as well (Figure
S8). Further, in five of the seven cases (Bcl-XL, IL-2, FKBP12,
ZipA, and XIAP) the conformations generated from the biased
simulations are closer than the starting unbound conformation to
an inhibitor-bound structure (Figure 5). Conformations sampled
in simulations of HPV E2 and MDM2 that moved further than the
unbound conformation from the inhibitor-bound structures may
be due to slight inaccuracies in the Rosetta energy function, or
alternatively may be sampling novel truly ‘‘druggable’’ conforma-
tions for which complementary inhibitors have not yet been
identified.
To further characterize the pockets generated using the biasing
potential, we evaluated the percentage of solvent accessible surface
area that is hydrophobic (hSASA) for each pocket (Figure S9).
While the hydrophobicity of the inhibitor-bound pockets vary
amongst the different protein test cases, in each case the pockets
generated using the biasing potential exhibit similar hydrophobic-
ity to the corresponding inhibitor-bound conformation. Like the
shape of these pockets, then, their hydrophobicity appears to be an
intrinsic property resulting from details of the surface geometry
and composition.
Collectively these results demonstrate that biasing simulations
towards conformations in which a surface pocket is present drives
the resulting ensemble towards the conformations observed in
inhibitor-bound crystal structures. Because no information about
the identity of any particular inhibitory compound was included in
the biasing potential, this suggests that the general shape (and
hydrophobicity) of surface pockets available to a potential inhibitor
is an inherent property of the druggable interface itself.
Druggability of survivin
The examples comprising our test set in the studies above were
selected on the basis of a known compound directly inhibiting a
protein interaction. For each of these cases, then, the druggable
site is coincident with the protein functional site. We next turned
to survivin, an example of a protein in which the two sites are non-
overlapping.
Survivin is among the most strongly tumor-specific proteins
known [35], is a notable signature of unfavorable disease outcome
[36], and has been well-validated as a therapeutic target using an
antisense oligonucleotide [37] and a transcriptional repressor
[38,39]. Despite this intense interest, however, no direct inhibitors
of survivin function have been identified. Survivin carries dual
functions which together explain its important role in cancer: it
serves as an inhibitor of apoptosis and is also required for cell
division [40]. The anti-apoptotic activity of survivin derives from
binding the Smac/DIABLO peptide via a BIR domain. While
small-molecule inhibitors of other Smac-binding BIR domains
have been identified [41–44] (we included the XIAP BIR domain
in the test set described in previous sections), efforts in this vein
using survivin have not yet proven fruitful [40,45]. Consistent with
a hypothesis that the peptide-binding surface of survivin may be
intrinsically undruggable, an SAR by NMR approach used by
Hajduk et al. found only a single probe that interacted with this
site (of 9,370 probes tested) – a full order of magnitude fewer than
the number of interacting probes found using proteins for which
potent inhibitors have been identified [14]. Intriguingly, this study
revealed a separate distal site (Figure 6A) at which 33 probe
Figure 5. Opening pockets shifts the conformational ensemble towards inhibitor-bound structures. Distributions of RMSD over
interface atoms (iRMSD) to the closest inhibitor-bound crystal structure for conformations generated with (red lines) or without (black lines) the
biasing potential. The iRMSDs from the unbound structure to the most and least similar inhibitor-bound crystal structures are also indicated (dashed
brown vertical lines). For all seven proteins comprising the test set, the biased simulations produced conformations closer to an inhibitor-bound
crystal structure than the unbiased simulations.
doi:10.1371/journal.pcbi.1002951.g005
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compounds bound, well within the frequency observed for
druggable sites on other proteins but not useful as a starting point
for modulating survivin function.
We carried out a series of biased simulations as described
earlier, using the unbound crystal structure of survivin as a starting
point. In agreement with results from SAR by NMR [14], we find
that pockets at the ‘‘undruggable’’ peptide-binding site of the BIR
domain do not form with any higher propensity than at randomly
selected equivalent surface sites (Figure 6B). This result is
particularly notable as it stands in contrast to our observations
from the XIAP BIR domain, in which surface pockets are formed
at the peptide-binding site (Figure 2G). Though beyond the scope
of the current work, we anticipate that further detailed studies may
reveal the precise origin of the differing propensity for binding
small-molecules exhibited by the peptide-binding groove of these
two highly similar BIR domains.
Though large surface pockets do not form at the peptide-
binding site of survivin, they do form readily at a specific alternate
site: the same distal surface identified by Hajduk et al. [14]
(Figure 6B, blue lines). Taken together, these studies of survivin
suggest that low-energy fluctuations that induce pocket formation
on the protein surface are indeed a primary determinant of
druggability at protein interaction sites rather than a signature of
the evolved protein-binding function of these sites.
Discussion
The results presented above support the hypothesis that the
conformational transitions that open pockets at a druggable site
occur with little energetic cost to the protein. This has two
important consequences.
First, pocket formation within the ensemble of physiological
protein fluctuations occurs only at a limited subset of surface sites.
Because pocket-containing conformations are rare, it is primarily
the lack of a suitable surface pocket – and not chemical
composition – that renders most protein surface sites undruggable.
The highly restricted druggability of protein surfaces supported by
both NMR [14] and crystallographic [15] observations that probe
molecules interact with a very limited subset of the protein surface.
Sites at which the unbound protein crystal structure includes a pre-
formed pocket (HPV E2, FKPB12, ZipA) typically exhibit only
minor conformational changes that change the size or shape of this
pocket, and are driven primarily by sidechain reorganization. In
contrast, for the examples in which the unbound protein crystal
structure does not have a pre-formed pocket or has only a small
surface pocket (XIAP, MDM2, Bcl-XL, IL-2) concerted motions
are needed that couple backbone conformational changes to the
sidechain reorganization that reveals the binding pocket. In both
cases, the biasing potential we describe here serves as a proxy for
the binding energy associated with some (unspecified) comple-
mentary compound, and thus drives sampling towards these
conformations.
Second, these results suggest that a small number of low-
resolution, low energy inhibitor shapes are encoded on the protein
surface through intrinsic structural and dynamic features of the
protein. We propose that low-energy fluctuations produce protein
conformations displaying one of these preferred shapes, at which
point a complementary small-molecule ligand may be accommo-
dated. The protein then responds to the particular steric and
chemical details of the ligand via subsequent smaller conforma-
tional changes, without changing the gross features of the pocket.
This model implies that exploring the pocket shapes may give
clues at low-resolution to the shapes of complementary ligands,
and may form the basis for a computational screening approach
that matches pocket shapes to potential inhibitory ligands.
As pointed out by Cheng and colleagues [46], pocket formation
is necessary but may not be sufficient for a protein surface to be
druggable: the curvature and hydrophobicity of the pocket are also
important. By applying their methodology to the pocket confor-
mations generated using the biasing potential described here, it
may be possible to filter for the most druggable conformations
from among these pocket-containing ensembles. These conforma-
tions may not necessarily correspond to the protein-bound
conformation, which has been used in some cases as a starting
point for mimicry by small-molecules [47]. Generating an
ensemble of druggable conformations for a given protein target
may prove valuable in identifying new inhibitory compounds, even
in cases where one or more inhibitors are already known. Rather
than aiming to identify additional inhibitors by analogy to these
known compounds, or even using the protein structure solved in
complex with one of these known compounds (or the natural
protein partner), matching directly against an ensemble of pocket-
containing conformations removes bias towards this parent
compound (or protein partner). We anticipate that the surface
pockets to which the protein is most predisposed, as revealed by
this approach and therefore identified without artifacts of
conformational changes in response to any particular binding
partner, may serve as an optimal starting point for computational
screening and may facilitate identification of chemotypes unrelated
to those of known inhibitors (‘‘scaffold hopping’’ [3,48]). These
new scaffolds may in turn yield potent novel small molecule
inhibitors through subsequent chemical elaboration.
In principle, fragment-based approaches allow multiple probe
molecules to be subsequently linked together to create a single
compound presenting these probe moieties in the appropriate
orientation [49]. Computational solvent mapping [27], while
suitable for assessing druggability in certain cases, may prove
limiting for early drug discovery because of its inability to explore
the concerted backbone motions necessary for thoroughly
sampling the ‘‘pocket ensemble’’. While FKBP sidechain motions
within 6 Å of the binding site are sufficient for recognizing small
probe molecules [49], the further necessity of backbone reorga-
nization in other cases described here (XIAP, MDM2, Bcl-XL, IL-
2) underscores the importance of backbone motions for confor-
mational fluctuations that reveal surface pockets. Exploring these
alternate conformations may further prove useful in guiding efforts
Figure 6. Distinguishing druggable from functional sites on
survivin. (A) The crystal structure of survivin, showing the protein
interaction site (red) and the distal druggable site identified by NMR
(blue) [14]. (B) Volumes of surface pockets are compared for
conformations generated with the biasing potential applied at random
surface residues (dashed black lines), applied at the protein interaction
site (dashed red lines), and applied at the distal druggable site (solid blue
lines). Pockets emerge at the druggable site but not elsewhere on the
protein surface.
doi:10.1371/journal.pcbi.1002951.g006
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to improve potency of known inhibitors, by identifying sites at
which substituents can make additional strong contacts with the
protein surface.
Finally, we note that the generality of our approach is conducive
to its large-scale application for comparing druggability across
many protein interaction sites. In the future, we expect this
approach may be used to address the outstanding question of
whether these few successful examples of small-molecules disrupt-
ing protein interaction sites are outliers, or whether they instead
represent the first step towards an important class of new tools for
therapeutic intervention.
Methods
Identifying pockets on protein surfaces
We implemented our modified version of the LIGSITEcs [28]
algorithm in the Rosetta software suite [34]. Briefly, a grid is
centered at the residue of interest on the protein surface and grid
points are marked as occupied by either protein (P) or solvent (S).
The algorithm performs linear searches in the X, Y and Z
directions as well as in each diagonal for ‘‘P-nS-P’’ events: cases
where a line no longer than 12 Å can be drawn between two
points on the protein surface that pass through only solvent,
establishing this solvent region as part of a surface pocket.
Subsequent additional criteria were used to eliminate spurious
definition of pockets and reduce the effect of grid-based artifacts
(described in Text S1). Adjoining grid points defined as ‘‘pocket’’
were clustered to determine the deep pocket volume of the largest
contiguous single pocket in contact with the target residue.
Simulation protocol
Simulations were carried out using the ‘‘relax’’ protocol [50] in
Rosetta, which incorporates both backbone and sidechain degrees
of freedom in a Monte Carlo search. To bias the simulations
towards pocket-containing conformations we added to the
standard energy function an additional energy term corresponding
to the current deep pocket volume multiplied by a proportionality
constant of 20.25 Rosetta energy units per Å3 (‘‘moderate’’ bias).
Simulations carried out with the ‘‘strong’’ bias used a proportion-
ality constant of 20.25 Rosetta energy units per Å3. Data for each
histogram was collected from 1,000 independent simulations. The
simulation protocol is described in complete detail in Text S1.
Supporting Information
Figure S1 Identifying pockets on protein surfaces
(complements Figure 1). A grid is centered at the residue of
interest on the protein surface (only partial grid is shown here).
Grid points are classified as either ‘‘protein’’ (grey background) or
‘‘solvent’’ (white background). Linear searches (red lines) are used to
identify and mark ‘‘protein-surface-protein’’ events (green gridpoints).
These are further classified based on degree of buried (light vs. dark
green) and adjoining grid points are clustered to yield discrete
‘‘pockets’’. Only a surface pocket in contact with the surface of the
‘‘target’’ residue (orange) contributes to the biasing potential.
(EPS)
Figure S2 Deep pocket volumes compared to Q-Site-
Finder pocket volumes (complements Figure 1). Deep
pocket volumes of surface pockets at protein interaction sites
harboring a bound inhibitor (red circles) and pockets found
elsewhere on the protein surface (black x’s) are plotted against the
corresponding pocket volumes identified by Q-SiteFinder, for each
of the sites used in Figure 1B. While the two are correlated, Q-
SiteFinder volumes are typically larger than the corresponding
deep pocket volumes.
(EPS)
Figure S3 Matching of random surface sites to protein
interaction sites (complements Figure 2). The distribution
of pocket volumes identified by Q-SiteFinder for the complete set
of random surface sites matched to the protein interaction sites on
the basis of burial and secondary structure is shown (black); the
corresponding pocket volumes for the protein interaction sites are
also shown (red arrows). In order to create a matched set, only
random sites with Q-SiteFinder pocket volumes greater than
100 Å3 were considered for Figures 2 and 3.
(EPS)
Figure S4 Surface pockets emerge only at druggable
sites, upon inclusion of additional random surface sites
(complements Figure 2). Pocket opening is not observed at
random surface sites upon inclusion of additional sites that were
previously excluded on the basis of Q-SiteFinder pocket volumes
less than 100 Å3 (dashed black lines). Symbols are as defined in
Figure 2. (A) Bcl-XL. (B) IL-2. (C) FKBP12. (D) HPV E2. (E)
ZipA. (F) MDM2. (G) BIR3 domain of XIAP.
(EPS)
Figure S5 Surface pockets emerge at druggable sites,
when starting from protein-bound conformations (com-
plements Figure 2). Simulations were carried out only applying
the biasing potential to the protein interaction site (red). With the
exception of XIAP, results are in agreement with simulations
started from the unbound protein structures (Figure 2). (A) Bcl-
XL. (B) IL-2. (C) FKBP12. (D) HPV E2. (E) ZipA. (F) MDM2. (G)
BIR3 domain of XIAP.
(EPS)
Figure S6 Energetic analysis of pocket opening for the
other members of our test set (complements Figure 3).
(A) Conformations generated using the biasing potential typically
have a distribution of energies that overlaps those generated with
the biasing potential, suggesting that these conformations
represent low-energy states accessible to the unbound protein.
(B) As with Bcl-xL, low-energy conformations containing large
pockets are not observed for the other members of our test set
unless the biasing potential is applied to the protein interaction
site. Symbols are as defined in Figure 3.
(TIF)
Figure S7 Representative conformations generated us-
ing the biasing potential (complements Figure 4). An
unbound crystal structure (pink), an inhibitor-bound crystal
structure (green, with inhibitor shown in sticks), and a low-energy
conformation generated from the unbound crystal structure using
the biasing potential (cyan, with target residue in red) are shown for
each of the proteins comprising our test set (except Bcl-XL, shown
in Figure 4). (A) IL-2. (B) FKBP12. (C) HPV E2. (D) ZipA. (E)
MDM2. (F) BIR3 domain of XIAP.
(TIF)
Figure S8 Opening pockets shifts the protein backbone
towards inhibitor-bound structures (complements
Figure 5). Distributions of backbone RMSD over interface
residues to the closest inhibitor-bound crystal structure for
conformations generated with (red lines) or without (black lines) the
biasing potential. The backbone RMSD over interface residues
from the unbound structure to the most and least similar inhibitor-
bound crystal structures are also indicated (dashed brown vertical lines).
(EPS)
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Figure S9 Hydrophobicity of pockets generated using
the biasing potential are similar to the corresponding
inhibitor-bound pockets (complements Figure 5). Distri-
butions of percentage hydrophobic solvent accessible surface area
(%hSASA) over interface atoms for conformations generated with
the biasing potential (red lines). The lowest and highest %hSASAs
from amongst all available inhibitor-bound crystal structures are
indicated (dashed green vertical lines). (A) Bcl-XL. (B) IL-2. (C)
FKBP12. (D) HPV E2. (E) ZipA. (F) MDM2. (G) BIR3 domain of
XIAP.
(EPS)
Text S1 Supplementary methods. This supporting text
contains a complete description of methodology used, including
PDB structures used in calculations. A description of pocket-
opened conformations for each protein in our test set is also
included in this text.
(DOC)
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